Antidepressant properties of antibodies to serotonin, brain-specific S100 protein, and delta sleep-inducing peptide.
Meshcheryakov. A F AF
Key Findings
- Antibodies that enhance DSIP activity produced an antidepressant‑like effect in Wistar rats.
- Combining DSIP‑targeting antibodies with antibodies to brain‑specific S100 protein gave a stronger effect than either alone.
- The results suggest that modulating DSIP and S100 pathways can influence emotional reinforcement and stress resilience.
Practical Outcomes
- For DIY health enthusiasts, the study hints that DSIP may play a role in mood regulation, but it used antibodies—not the peptide itself—so there’s no direct dosing guidance. It’s a modest piece of evidence supporting further exploration of DSIP for mood or stress, but more human data are needed before it can be turned into a reliable protocol.
Summary
In rats, giving antibodies that boost the activity of the brain peptide delta sleep‑inducing peptide (DSIP) and a related protein reduced signs of depression, especially when both were used together. The researchers think these antibodies may tweak brain pathways that control positive emotions and stress resistance.
Abstract
Potentiated antibodies to delta sleep-inducing peptide and S100 protein produced an antidepressant effect in Wistar rats. This effect was more pronounced after combined treatment with these antibodies. It can be assumed that these antibodies modulate neurobiological mechanisms of positive emotional reinforcement and, therefore, affect the resistance to depression associated with psychoemotional stress.
Study Information
pubmed
2003
10.1023/a:1024749906789